The Defender
Cathelicidin Antimicrobial Peptide (hCAP18 active form)
LL-37 is the only human cathelicidin antimicrobial peptide, produced by neutrophils, macrophages, and epithelial cells as a first-line immune defense. It has broad-spectrum antimicrobial activity against bacteria, viruses, and fungi, and plays a critical role in the innate immune system. LL-37 is unique in its ability to disrupt bacterial biofilms, making it valuable for chronic and resistant infections.
LL-37 kills pathogens through direct membrane disruption while also modulating the immune response to enhance pathogen clearance. Its ability to penetrate and disrupt biofilms addresses one of the most challenging aspects of chronic infections.
Directly disrupts microbial cell membranes through electrostatic interaction and pore formation, killing bacteria, viruses, and fungi on contact.
Penetrates and disrupts bacterial biofilms — the protective matrix that makes chronic infections resistant to conventional antibiotics.
Activates and recruits immune cells to infection sites through chemotactic signaling, amplifying the immune response.
Neutralizes bacterial endotoxins (LPS), reducing the inflammatory damage caused by bacterial cell wall components.
Direct killing activity against gram-positive and gram-negative bacteria, enveloped viruses, and fungal pathogens through membrane disruption.
Uniquely capable of penetrating and disrupting bacterial biofilms, addressing chronic infections that resist conventional antibiotic therapy.
Recruits and activates immune cells, enhancing the body's natural defense response beyond direct antimicrobial killing.
Promotes wound healing through both antimicrobial protection and stimulation of cell migration and angiogenesis at wound sites.
LL-37 demonstrated potent antimicrobial activity against multidrug-resistant bacterial strains including MRSA, with minimal development of resistance.
LL-37 disrupted established Pseudomonas aeruginosa biofilms at concentrations below its minimum inhibitory concentration, showing unique anti-biofilm properties.
Topical LL-37 application significantly improved healing of chronic venous leg ulcers in a Phase I/II clinical trial, with both antimicrobial and wound healing benefits.
LL-37 is a naturally occurring component of the human immune system. Therapeutic use involves supplementing what the body already produces. Safety considerations primarily relate to ensuring proper dosing to avoid potential pro-inflammatory effects at high concentrations.
Research Status
LL-37 has extensive basic science research and is well-characterized as a natural immune component. Clinical applications are in early stages, with Phase I/II trials for wound healing. Antimicrobial applications are an active area of drug development.
Regulatory Note
Not FDA-approved as a therapeutic. Available as a research compound through compounding pharmacies. Several LL-37-based therapeutics are in pharmaceutical development pipelines.